Causeway Sensors have been awarded an Innovate UK funded Knowledge Transfer Partnership (KTP) in conjunction with Professor Chris Scott (Queen’s University Belfast). Professor Chris Scott is Chair of Pharmaceutical Biosciences and the Centre for Cancer Research and Cell Biology. Chris is internationally renowned for his work in development of genetically engineered protein and antibody-based therapies and nanomedicine-based therapies for the treatment of cancer and other conditions.
This unique opportunity allows Causeway Sensors to deploy their cutting edge nanostructure technology into the world of precision medicine in cancer diagnosis and treatment. The project will leverage Professor Scott’s expertise in nanomedicine and expose Causeway’s platform to the rigours of world leading research and development. The project will run for 3 years and look at amplifying the detection of proteins using nanoparticles.